[go: up one dir, main page]

WO2002083112A3 - Method for the treatment of polycystic kidney disease - Google Patents

Method for the treatment of polycystic kidney disease Download PDF

Info

Publication number
WO2002083112A3
WO2002083112A3 PCT/US2002/010751 US0210751W WO02083112A3 WO 2002083112 A3 WO2002083112 A3 WO 2002083112A3 US 0210751 W US0210751 W US 0210751W WO 02083112 A3 WO02083112 A3 WO 02083112A3
Authority
WO
WIPO (PCT)
Prior art keywords
kidney disease
polycystic kidney
treatment
patient
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/010751
Other languages
French (fr)
Other versions
WO2002083112A2 (en
Inventor
Philip Frost
Jeremy Ian Levin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Wyeth LLC
Original Assignee
Wyeth Holdings LLC
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings LLC, Wyeth LLC filed Critical Wyeth Holdings LLC
Priority to US10/473,857 priority Critical patent/US7488754B2/en
Priority to AU2002256095A priority patent/AU2002256095A1/en
Priority to BR0208784-7A priority patent/BR0208784A/en
Publication of WO2002083112A2 publication Critical patent/WO2002083112A2/en
Publication of WO2002083112A3 publication Critical patent/WO2002083112A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a method for treating, inhibiting the progression of, or eradicating polycystic kidney disease of in a patient in need thereof which comprises providing to said patient an effective amount of a TACE inhibitor compound alone or in combination with an effective amount of an EGF receptor kinase inhibitor.
PCT/US2002/010751 2001-04-11 2002-04-05 Method for the treatment of polycystic kidney disease Ceased WO2002083112A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/473,857 US7488754B2 (en) 2002-04-05 2002-04-05 Method for the treatment of polycystic kidney disease
AU2002256095A AU2002256095A1 (en) 2001-04-11 2002-04-05 Method for the treatment of polycystic kidney disease
BR0208784-7A BR0208784A (en) 2001-04-11 2002-04-05 Method for treating, inhibiting progression or eradicating polycystic kidney disease in a mammal in need thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28308701P 2001-04-11 2001-04-11
US60/283,087 2001-04-11

Publications (2)

Publication Number Publication Date
WO2002083112A2 WO2002083112A2 (en) 2002-10-24
WO2002083112A3 true WO2002083112A3 (en) 2003-09-25

Family

ID=23084450

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/010751 Ceased WO2002083112A2 (en) 2001-04-11 2002-04-05 Method for the treatment of polycystic kidney disease

Country Status (4)

Country Link
AU (1) AU2002256095A1 (en)
BR (1) BR0208784A (en)
CA (1) CA2357110A1 (en)
WO (1) WO2002083112A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2428509A1 (en) 2002-06-12 2012-03-14 Symphony Evolution, Inc. Human adam-10 inhibitors
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
GT200500139A (en) * 2004-06-08 2005-07-25 METHOD FOR THE PREPARATION OF HYDROXAMIC ACIDS
BRPI0512496A (en) * 2004-06-23 2008-03-04 Genzyme Corp processes and compositions for the treatment of polycystic diseases
TW200616612A (en) * 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
WO2000044709A2 (en) * 1999-01-27 2000-08-03 American Cyanamid Company ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS
WO2000044710A2 (en) * 1999-01-27 2000-08-03 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
WO2000044730A1 (en) * 1999-01-27 2000-08-03 American Cyanamid Company 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
WO2001010827A1 (en) * 1999-08-09 2001-02-15 Novartis Ag Arylsulfonamido-substituted hydroxamic acid derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
WO2000044709A2 (en) * 1999-01-27 2000-08-03 American Cyanamid Company ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS
WO2000044710A2 (en) * 1999-01-27 2000-08-03 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
WO2000044730A1 (en) * 1999-01-27 2000-08-03 American Cyanamid Company 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
WO2001010827A1 (en) * 1999-08-09 2001-02-15 Novartis Ag Arylsulfonamido-substituted hydroxamic acid derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DELL K M ET AL: "A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease.", KIDNEY INTERNATIONAL. UNITED STATES OCT 2001, vol. 60, no. 4, October 2001 (2001-10-01), pages 1240 - 1248, XP002223746, ISSN: 0085-2538 *
OBERMUELLER, NICHOLAS ET AL: "A possible role for metalloproteinases in renal cyst development.", AMERICAN JOURNAL OF PHYSIOLOGY, (MARCH, 2001) VOL. 280, NO. 3 PART 2, PP. F540-F550. PRINT., XP002223744 *
QIAN Q. ET AL: "Treatment prospects for autosomal-dominant polycystic kidney disease.", KIDNEY INTERNATIONAL, (2001) 59/6 (2005-2022)., XP002223745 *

Also Published As

Publication number Publication date
CA2357110A1 (en) 2002-10-11
WO2002083112A2 (en) 2002-10-24
AU2002256095A1 (en) 2002-10-28
BR0208784A (en) 2004-06-22

Similar Documents

Publication Publication Date Title
WO2006042100A3 (en) Method for the treatment of polycystic kidney disease
WO2001060347A3 (en) Method for treating ocular pain
MXPA04004969A (en) 3-cyanoquinolines as inhibitors of egf-r and her2 kinases.
WO2004105700A3 (en) Compounds, methods and pharmaceutical compositions for inhibiting parp
WO2002100347A3 (en) Prodrugs of gaba analogs, compositions and uses thereof
SI1638941T1 (en) Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2007075783A3 (en) Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
WO2002083064A3 (en) A method of treating cancer
AU2002325835A1 (en) Treatment method, which promotes the removal of dirt, for the surfaces of textiles and non-textiles
WO2004009559A3 (en) Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents
WO2000043373A3 (en) Kinase inhibitors
WO2001081343A3 (en) Compounds for treating fibromyalgia and chronic fatigue syndrome
WO2003006893A3 (en) Methods of inhibiting amyloid toxicity
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2006078711A3 (en) Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp
WO2002073208A3 (en) Anti-epileptogenic agents
WO2004021988A3 (en) Treatment of pain by inhibition of p38 map kinase
WO2004084842A3 (en) Inhibitors of cathepsin s
WO2003033557A3 (en) Copolymers containing fluorine, method for the production and use thereof
WO2004032908A3 (en) Method of inhibiting angiogenesis
AP2003002834A0 (en) Method of treating of demyelinating disease or conditions.
WO2002083112A3 (en) Method for the treatment of polycystic kidney disease
WO2002083842A3 (en) Small molecule inhibitors of secretion of proteins encoded by are-mrnas
AU2002320352A1 (en) Methods for treating or preventing sclerotic disorders using cd2-binding agents
WO2002051855A3 (en) Motilide compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10473857

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP